DE69316369D1 - Oligonukleotid alkylphosphonothiate - Google Patents

Oligonukleotid alkylphosphonothiate

Info

Publication number
DE69316369D1
DE69316369D1 DE1993616369 DE69316369A DE69316369D1 DE 69316369 D1 DE69316369 D1 DE 69316369D1 DE 1993616369 DE1993616369 DE 1993616369 DE 69316369 A DE69316369 A DE 69316369A DE 69316369 D1 DE69316369 D1 DE 69316369D1
Authority
DE
Germany
Prior art keywords
alkylphosphonothiate
oligonukleotid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1993616369
Other languages
English (en)
Inventor
A Padmapriya
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idera Pharmaceuticals Inc
Original Assignee
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US91996792A priority Critical
Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc
Priority to PCT/US1993/006976 priority patent/WO1994002499A1/en
Application granted granted Critical
Publication of DE69316369D1 publication Critical patent/DE69316369D1/de
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
DE1993616369 1992-07-27 1993-07-26 Oligonukleotid alkylphosphonothiate Expired - Lifetime DE69316369D1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US91996792A true 1992-07-27 1992-07-27
PCT/US1993/006976 WO1994002499A1 (en) 1992-07-27 1993-07-26 Oligonucleotide alkylphosphonothioates

Publications (1)

Publication Number Publication Date
DE69316369D1 true DE69316369D1 (de) 1998-02-19

Family

ID=25442953

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1993616369 Expired - Lifetime DE69316369D1 (de) 1992-07-27 1993-07-26 Oligonukleotid alkylphosphonothiate

Country Status (9)

Country Link
US (1) US5929226A (de)
EP (1) EP0652890B1 (de)
JP (1) JPH08502723A (de)
AT (1) AT162198T (de)
AU (1) AU678769B2 (de)
CA (1) CA2140542A1 (de)
DE (1) DE69316369D1 (de)
RU (1) RU95104940A (de)
WO (1) WO1994002499A1 (de)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067497B2 (en) * 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150D0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
AT150464T (de) * 1993-01-08 1997-04-15 Hybridon Inc Synthese von dimer-blöcken und ihre verwendung bei der zusammensetzung von oligonukleotiden
US6087491A (en) * 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
AT138384T (de) * 1993-01-25 1996-06-15 Hybridon Inc Olionukleotidalkylphosphonate und - phosphonothioate
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
JPH09505306A (ja) * 1993-11-16 1997-05-27 ジンタ・インコーポレイテッド 非ホスホネートヌクレオシド間結合と混合している不確定キラリティーのホスホネートヌクレオシド間結合を有する合成オリゴマー
JPH09505307A (ja) * 1993-11-16 1997-05-27 ジンタ・インコーポレイテッド 多キラル合成フォスホネートオリゴマー類
WO1995014030A1 (en) * 1993-11-16 1995-05-26 Genta Incorporated Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
ES2267100T5 (es) 1994-07-15 2011-04-08 Coley Pharmaceutical Group, Inc. Oligonucleótidos inmunomoduladores.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
AU5319396A (en) * 1995-03-23 1996-10-08 Hybridon, Inc. Thiono triester modified antisense oligodeoxynucleotide phosphorothioates
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US6624293B1 (en) 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US7074768B2 (en) 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU4156197A (en) * 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
ES2317710T3 (es) * 1998-11-05 2009-04-16 Thomas Jefferson University Tratamiento de la enfermedad de parkinson con oligonucleotidos.
EP2298728A1 (de) 1998-11-12 2011-03-23 Life Technologies Corporation Transfektionsreagenzien
US20050136458A1 (en) * 1998-12-31 2005-06-23 Oligos, Etc, Inc. Method for nucleic acid preparation
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6372722B1 (en) 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
AU3238702A (en) * 2000-10-27 2002-05-06 Invitrogen Corp Method for introducing antisense oligonucleotides into eucaryotic cells
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
EP2270024B1 (de) 2001-06-21 2018-10-24 Ionis Pharmaceuticals, Inc. Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
EP2196217A1 (de) 2001-09-14 2010-06-16 Cytos Biotechnology AG Verpackung von immunstimulierenden Mitteln in virusähnischen Partikeln: Herstellungsverfahren und Verwendung
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2270231A3 (de) 2001-10-09 2011-04-27 ISIS Pharmaceuticals, Inc. Antisense Modulation der Expression von insulin-like growth factor binding protein 5
DK1456380T3 (da) * 2001-11-02 2012-07-30 Giuliani Int Ltd SMAD7-inhibitorer til behandling af CNS-sygdomme
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
JP4986109B2 (ja) 2002-11-13 2012-07-25 ジェンザイム・コーポレーション アポリポタンパク質b発現のアンチセンス調節
PT2336318E (pt) 2002-11-13 2013-06-12 Genzyme Corp Modulação anti-sentido da expressão de apolipoproteína b
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20030220844A1 (en) * 2002-05-24 2003-11-27 Marnellos Georgios E. Method and system for purchasing genetic data
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CA2498777C (en) 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2004031350A2 (en) 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
EP1552025A4 (de) * 2002-10-18 2006-12-13 Cylene Pharmaceuticals Inc Verfahren zur identifizierung von mittels einer quadruplexstruktur erkannten antiviralen molekülen
WO2004043979A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP1560839A4 (de) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Chimäre oligomere verbindungen und derenverwendung in der genmodulation
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US20060253917A1 (en) 2002-12-26 2006-11-09 Bret Cooper Cell proliferation-related polypeptides and uses therefor
CA2515484C (en) 2003-02-11 2011-09-20 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2005002507A2 (en) 2003-06-03 2005-01-13 Isis Pharmaceuticals, Inc. Modulation of survivin expression
EP2530157B1 (de) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20050095627A1 (en) * 2003-09-03 2005-05-05 The Salk Institute For Biological Studies Multiple antigen detection assays and reagents
CN100558893C (zh) 2003-09-18 2009-11-11 Isis 药物公司;伊莱利利公司 eIF4E表达的调节
EP1663316A2 (de) * 2003-09-25 2006-06-07 Coley Pharmaceutical Group, Inc. Nucleinsäure-lipophile konjugate
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
JP2007520222A (ja) 2004-01-20 2007-07-26 アイシス ファーマシューティカルズ インコーポレイテッド グルココルチコイドレセプター発現の調節
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
AU2005286738A1 (en) 2004-09-17 2006-03-30 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
RU2451523C2 (ru) 2005-12-14 2012-05-27 Цитос Биотехнологи Аг Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007134014A2 (en) 2006-05-05 2007-11-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of gcgr
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
EP2114981B1 (de) 2007-01-29 2013-05-08 Isis Pharmaceuticals, Inc. Verbindungen und Methoden zur Modulation der Proteinexpression
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
CN101821277B (zh) 2007-08-15 2014-05-07 Isis制药公司 四氢吡喃核酸类似物
CA2700953A1 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
USRE47320E1 (en) 2007-11-20 2019-03-26 Ionis Pharmaceuticals, Inc. Modulation of CD40 expression
WO2009091934A1 (en) * 2008-01-17 2009-07-23 Sequenom, Inc. Single molecule nucleic acid sequence analysis processes and compositions
WO2009114543A2 (en) * 2008-03-11 2009-09-17 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
EP2282744B1 (de) 2008-03-21 2018-01-17 Ionis Pharmaceuticals, Inc. Oligomere verbindungen mit trizyklischen nukleosiden und anwendungsverfahren dafür
EP2274423A2 (de) 2008-04-04 2011-01-19 Isis Pharmaceuticals, Inc. Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
US8476013B2 (en) * 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8604192B2 (en) 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010048549A2 (en) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2010091308A2 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
CA2785020A1 (en) 2009-12-22 2011-07-21 Sequenom, Inc. Processes and kits for identifying aneuploidy
US8779118B2 (en) 2010-01-11 2014-07-15 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
US9193752B2 (en) 2010-03-17 2015-11-24 Isis Pharmaceuticals, Inc. 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
EP2606057B1 (de) 2010-04-28 2016-06-15 Ionis Pharmaceuticals, Inc. Modifizierte 5' diphosphat-nukleoside und daraus hergestellte oligomere verbindungen
EP3091027B1 (de) 2010-04-28 2018-01-17 Ionis Pharmaceuticals, Inc. 5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
JP6005628B2 (ja) 2010-04-28 2016-10-12 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
JP5896175B2 (ja) 2010-04-29 2016-03-30 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. トランスサイレチン発現の調節
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US8450061B2 (en) 2011-04-29 2013-05-28 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2742136B1 (de) 2011-08-11 2017-09-27 Ionis Pharmaceuticals, Inc. Gapmerverbindungen mit 5'-modifizierten desoxyribonukleotiden im gap und verwendungen davon
DK2751270T3 (da) 2011-08-29 2018-10-29 Ionis Pharmaceuticals Inc Oligomer-konjugatkomplekser og deres anvendelse
DK2756080T3 (da) 2011-09-14 2019-05-20 Translate Bio Ma Inc Multimeriske oligonukleotidforbindelser
WO2013131021A1 (en) 2012-03-02 2013-09-06 Sequenom Inc. Methods and processes for non-invasive assessment of genetic variations
EP2639238A1 (de) 2012-03-15 2013-09-18 Universität Bern Tricyclische Nukleoside und daraus hergestellte oligomere Verbindungen
WO2013154798A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850185A4 (de) 2012-05-16 2015-12-30 Rana Therapeutics Inc Zusammensetzungen und verfahren zur modulation der utrn-genexpression
EP2850186B1 (de) 2012-05-16 2018-12-19 Translate Bio MA, Inc. Zusammensetzungen und verfahren zur modulation der expression der smn-genfamilie
WO2013173598A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
JP2015518710A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
CN104540944A (zh) 2012-05-21 2015-04-22 斯克利普斯研究所 核糖体多核苷酸和相关表达系统
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
NZ631552A (en) 2013-05-01 2017-02-24 Ionis Pharmaceuticals Inc Compositions and methods for modulating hbv expression
WO2015051283A1 (en) 2013-10-04 2015-04-09 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
RU2016117978A (ru) 2013-10-11 2017-11-17 Дженентек, Инк. Ингибиторы nsp4 и способы их применения
WO2015142910A1 (en) 2014-03-17 2015-09-24 Isis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
US10221416B2 (en) 2014-04-24 2019-03-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168172A1 (en) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
JP2017514489A (ja) 2014-05-01 2017-06-08 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 補体b因子発現を調節するための組成物及び方法
BR112016024850A2 (pt) 2014-05-01 2017-10-24 Ionis Pharmaceuticals Inc composições e métodos para modulação da expressão 3 semelhante a antiopoietina
JP2017522010A (ja) 2014-06-10 2017-08-10 エラスムス ユニバーシティ メディカルセンター ロッテルダムErasmus University Medical Center Rotterdam ポンペ病の治療に有用なアンチセンスオリゴヌクレオチド
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
JP2018518491A (ja) 2015-06-12 2018-07-12 アレクトル エルエルシー 抗cd33抗体及びその使用方法
US20190002560A1 (en) 2015-06-12 2019-01-03 Alector Llc Anti-cd33 antibodies and methods of use thereof
US20180244770A1 (en) 2015-08-28 2018-08-30 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
WO2017099579A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865641A (en) * 1972-01-14 1975-02-11 Lake Chemical Co Compositions for use in soldering stainless steels
JPS5510016A (en) * 1978-07-06 1980-01-24 Nissan Motor Co Ltd Fuel injection valve
US4757055A (en) * 1980-11-12 1988-07-12 The Johns Hopkins University Method for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
JPS5845597A (en) * 1981-09-14 1983-03-16 Hitachi Ltd Device for managing entrance and exit of room
JPS58195057A (en) * 1982-05-07 1983-11-14 Toyota Motor Corp Assist air control method for internal-combustion engine
JPS5946366A (en) * 1982-09-07 1984-03-15 Hitachi Ltd Feeding device for mixed gas
DE3332068A1 (de) * 1983-09-06 1985-03-21 Hoechst Ag Verfahren zur herstellung von nukleosidalkyl-, aralkyl- und arylphosphoniten und -phosphonaten
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
JPS63106356A (en) * 1986-10-23 1988-05-11 Mazda Motor Corp Fuel feed device for engine
DE68925278T2 (de) * 1988-02-26 1996-09-19 Worcester Found Ex Biology Hemmung von htlv-iii durch exogene oligonukleotide
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
US5449769A (en) * 1989-03-06 1995-09-12 Gen-Probe Incorporated Method and reagent for sulfurization of organophosphorous compounds
KR920701230A (ko) * 1989-06-05 1992-08-11 원본미기재 엑소뉴클레아제-내성 올리고뉴클레오티드 및 그 제조방법
US5003097A (en) * 1989-10-02 1991-03-26 The United States Of America As Represented By The Department Of Health And Human Services Method for the sulfurization of phosphorous groups in compounds
JPH04154794A (en) * 1990-10-15 1992-05-27 Yodogawa Seiyaku Kk Antisensoligodeoxyribonucleotide and hiv activity inhibitor containing the same nucleotide as active ingredient

Also Published As

Publication number Publication date
CA2140542A1 (en) 1994-02-03
AT162198T (de) 1998-01-15
AU678769B2 (en) 1997-06-12
RU95104940A (ru) 1997-01-10
JPH08502723A (ja) 1996-03-26
WO1994002499A1 (en) 1994-02-03
AU4688393A (en) 1994-02-14
EP0652890A1 (de) 1995-05-17
US5929226A (en) 1999-07-27
EP0652890B1 (de) 1998-01-14

Similar Documents

Publication Publication Date Title
DE69332083D1 (en) Polyolefinfasern
DE69307495D1 (de) Oligothionukleotide
DE69316369D1 (de) Oligonukleotid alkylphosphonothiate
DE69307690D1 (de) Implantierbare penis-prothese
DE69325018D1 (de) Pyrazolderivate
DE69310146D1 (en) Riemenspannvorreichtung
DE69319731D1 (de) Wässrige polyurethan-dispersionen
DE69320476D1 (de) Erythromycinderivate
AP9300508A0 (en) Compounds
GB9209628D0 (en) Compounds
GB2269063B (en) Auto-reclosers
TW272940B (en) /
PL175111B1 (xx) Nowe taksoidy
GB2267325B (en) Autotensioner
DE69330823D1 (de) Thiacyclische piperidinylderivate
HU9303423D0 (en) Catechin-diether-type pdeiv-inhibitors
HU9303515D0 (en) Pyrrolo-pyrimidines
HUT67279A (en) Powder-inhaler
HU9303579D0 (en) Resin-free-succinimides
HU9300184D0 (en) Amin-oxides
DE69313449D1 (de) Akarizid
ZA9307780B (en) Substituted benzylaminoquinuclidines
HUT68483A (en) Vintilated filtercigarette
DE69306746D1 (en) Schlichtmittelzusammensetzung
IL119715D0 (en) 5- hydroxy -3- phenyl - thiazolidin -4- ones

Legal Events

Date Code Title Description
8332 No legal effect for de